IL128439A - Solid foamed active ingredient preparations and processes for producing such preparations - Google Patents

Solid foamed active ingredient preparations and processes for producing such preparations

Info

Publication number
IL128439A
IL128439A IL12843997A IL12843997A IL128439A IL 128439 A IL128439 A IL 128439A IL 12843997 A IL12843997 A IL 12843997A IL 12843997 A IL12843997 A IL 12843997A IL 128439 A IL128439 A IL 128439A
Authority
IL
Israel
Prior art keywords
preparations
active ingredient
pct
processes
producing
Prior art date
Application number
IL12843997A
Other languages
English (en)
Other versions
IL128439A0 (en
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of IL128439A0 publication Critical patent/IL128439A0/xx
Publication of IL128439A publication Critical patent/IL128439A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
    • C08J9/04—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof using blowing gases generated by a previously added blowing agent
    • C08J9/12—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof using blowing gases generated by a previously added blowing agent by a physical blowing agent
    • C08J9/122—Hydrogen, oxygen, CO2, nitrogen or noble gases
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2339/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Derivatives of such polymers
    • C08J2339/04—Homopolymers or copolymers of monomers containing heterocyclic rings having nitrogen as ring member
    • C08J2339/06—Homopolymers or copolymers of N-vinyl-pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
IL12843997A 1996-09-03 1997-08-21 Solid foamed active ingredient preparations and processes for producing such preparations IL128439A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19635676A DE19635676A1 (de) 1996-09-03 1996-09-03 Feste geschäumte Wirkstoffzubereitungen
PCT/EP1997/004550 WO1998009616A1 (de) 1996-09-03 1997-08-21 Feste geschäumte wirkstoffzubereitungen

Publications (2)

Publication Number Publication Date
IL128439A0 IL128439A0 (en) 2000-01-31
IL128439A true IL128439A (en) 2003-02-12

Family

ID=7804471

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12843997A IL128439A (en) 1996-09-03 1997-08-21 Solid foamed active ingredient preparations and processes for producing such preparations

Country Status (22)

Country Link
US (1) US6150424A (pt)
EP (1) EP0932393B1 (pt)
JP (1) JP2000517327A (pt)
CN (1) CN1124129C (pt)
AT (1) ATE215362T1 (pt)
AU (1) AU740856B2 (pt)
BG (1) BG103214A (pt)
BR (1) BR9711982A (pt)
CA (1) CA2264588C (pt)
CZ (1) CZ67699A3 (pt)
DE (2) DE19635676A1 (pt)
DK (1) DK0932393T3 (pt)
ES (1) ES2175469T3 (pt)
HR (1) HRP970472A2 (pt)
HU (1) HUP9904101A3 (pt)
IL (1) IL128439A (pt)
NO (1) NO991011L (pt)
PT (1) PT932393E (pt)
RU (1) RU2200004C2 (pt)
TR (1) TR199900447T2 (pt)
WO (1) WO1998009616A1 (pt)
ZA (1) ZA977861B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19733505A1 (de) 1997-08-01 1999-02-04 Knoll Ag Schnell wirksames Analgeticum
DE19900457A1 (de) * 1999-01-08 2000-07-13 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
US6733789B1 (en) 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
CA2359945C (en) 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
US20040185099A1 (en) * 2000-01-20 2004-09-23 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
DE10032456A1 (de) 2000-07-04 2002-01-31 Lohmann Therapie Syst Lts Schnell zerfallende Darreichungsform zur Freisetzung von Wirkstoffen im Mundraum oder in Körperhöhlen
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
GB0113841D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
US20030198671A1 (en) * 2001-08-10 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique plasma AUC properties
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030171436A1 (en) * 2001-10-29 2003-09-11 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
US20030118652A1 (en) * 2001-11-15 2003-06-26 John Kelly Methods and compositions for use of (S)-bisoprolol
US20030091633A1 (en) * 2001-11-15 2003-05-15 John Kelly Methods and compositions for use of (S)-bisoprolol
EP1478345A4 (en) * 2002-01-03 2010-11-17 Glaxosmithkline Llc NOVEL PHARMACEUTICAL DOSAGE FORMS AND PROCESS FOR PRODUCTION OF SAID DOSAGE FORMS
DE10207394B4 (de) 2002-02-21 2007-03-29 Lts Lohmann Therapie-Systeme Ag Geschmacksmaskierte oblatenförmige Arzneizubereitung
US20030235613A1 (en) * 2002-06-19 2003-12-25 Cts Chemical Industries Ltd. Popping oral administration form
DE10227607A1 (de) * 2002-06-20 2004-01-08 Boxler Gmbh & Co. Kg Paneel-Verbindung
US7833775B2 (en) 2003-02-06 2010-11-16 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US7695725B2 (en) * 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
KR101192652B1 (ko) * 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
WO2004112756A1 (en) 2003-06-26 2004-12-29 Isa Odidi Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
WO2005023215A2 (en) * 2003-09-10 2005-03-17 Janssen Pharmaceutica N.V. Particles shaped as platelets
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
FR2886938B1 (fr) * 2005-06-10 2008-04-18 Armines Ass Loi De 1901 Procede d'extrusion permettant de fabriquer des dispersions solides de principes actifs pharmaceutiques dans une matrice polymere
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
RU2589823C2 (ru) * 2009-04-09 2016-07-10 Алкермес Фарма Айэленд Лимитед Композиция для доставки лекарственных средств
CA2786819A1 (en) * 2010-01-13 2011-07-21 Jazz Pharmaceuticals Plc Method for titrating clozapine
WO2011117740A2 (en) 2010-03-26 2011-09-29 Philip Morris Products S.A. Inhibition of sensory irritation during consumption of non-smokeable tobacco products
US8952038B2 (en) 2010-03-26 2015-02-10 Philip Morris Usa Inc. Inhibition of undesired sensory effects by the compound camphor
WO2011144727A1 (de) * 2010-05-21 2011-11-24 Basf Se ZUBEREITUNGEN BIOLOGISCH AKTIVER SUBSTANZEN MIT VERGRÖßERTER OBERFLÄCHE AUF BASIS VON AMPHIPHILEN COPOLYMEREN
CN102906169A (zh) * 2010-05-21 2013-01-30 巴斯夫欧洲公司 基于药学上可接受热塑性可加工聚合物的含活性成分的纳米多孔发泡制剂
EP2571490A2 (en) * 2010-05-21 2013-03-27 President and Fellows of Harvard College Foam or particles for applications such as drug delivery
US8636929B2 (en) 2010-05-21 2014-01-28 Basf Se Nanoporous foamed active compound-containing preparations based on pharmaceutically acceptable thermoplastically workable polymers
EP2463327A3 (de) * 2010-12-10 2015-06-03 Basf Se Verfahren zur herstellung von granulaten, enthaltend mindestens eine wasserlösliche komponente
AU2012229476B2 (en) 2011-03-01 2016-02-25 The Procter & Gamble Company Porous disintegratable solid substrate for personal health care applications
EP3137113A4 (en) * 2014-04-30 2017-03-22 Blaesi, Aron H. Melt-processed polymeric cellular dosage form
WO2019069108A1 (en) * 2017-10-04 2019-04-11 Debreceni Egyetem SOLID GALENIC FORM, MOLDED, GASTRIC RETENTION AND EXTENDED RELEASE AND METHOD OF PREPARING THE SAME
DE102020110089A1 (de) * 2020-04-09 2021-10-14 Karl-Franzens-Universität Graz Verfahren zum Herstellen eines porösen Wirkstoffträgers mittels Heißschmelzextrusion

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
DE3612211A1 (de) * 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
IT1247529B (it) * 1991-04-24 1994-12-17 Poli Ind Chimica Spa Composizioni farmaceutiche in forma di schiuma per somministrazione intravaginale, cutanea e orale
JP2966735B2 (ja) * 1994-07-29 1999-10-25 積水化成品工業株式会社 熱可塑性樹脂押出機

Also Published As

Publication number Publication date
WO1998009616A1 (de) 1998-03-12
HUP9904101A2 (hu) 2000-04-28
CZ67699A3 (cs) 1999-05-12
US6150424A (en) 2000-11-21
AU4617797A (en) 1998-03-26
DE19635676A1 (de) 1998-03-05
AU740856B2 (en) 2001-11-15
ES2175469T3 (es) 2002-11-16
HUP9904101A3 (en) 2001-11-28
CA2264588A1 (en) 1998-03-12
CN1124129C (zh) 2003-10-15
TR199900447T2 (xx) 1999-05-21
PT932393E (pt) 2002-09-30
CN1237103A (zh) 1999-12-01
DK0932393T3 (da) 2002-07-01
BR9711982A (pt) 1999-08-24
NO991011D0 (no) 1999-03-02
BG103214A (en) 1999-09-30
CA2264588C (en) 2005-10-18
HRP970472A2 (en) 1998-08-31
EP0932393A1 (de) 1999-08-04
EP0932393B1 (de) 2002-04-03
JP2000517327A (ja) 2000-12-26
RU2200004C2 (ru) 2003-03-10
DE59706898D1 (de) 2002-05-08
ZA977861B (en) 1999-03-02
IL128439A0 (en) 2000-01-31
NO991011L (no) 1999-03-03
ATE215362T1 (de) 2002-04-15

Similar Documents

Publication Publication Date Title
IL128439A (en) Solid foamed active ingredient preparations and processes for producing such preparations
EP0621706A3 (en) System and method for monitoring simple network management protocol tables.
PT896534E (pt) Formulacoes para injeccao de avermectinas e milbemicinas a base de oleo de ricino
CA2129193A1 (en) Access Point Tracking for Mobile Wireless Network Node
CA2105887A1 (en) Bioerodible device for administering active ingredients
CA2143431A1 (en) Space Keeper, in Particular for an Intervertebral Disk
MX9802383A (es) Derivados de pirimidina como antagonistas del receptor 5ht26.
CA2263404A1 (en) Pharmaceutical composition comprising coenzyme q10
WO2004025887A3 (en) Network access points using multiple devices
AU7080098A (en) Apatite-coated solid composition
AU2093797A (en) Wood preservative for afterprotection
AU3716297A (en) Substituted tetrahydronaphthalene and dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
CY2476B1 (en) Benzonaphthyridines as bronchial therapeutics.
ATE212971T1 (de) Schmelzbare stabilisatorkombination
CA2199103A1 (en) Data processing system and data processing method
AU4088097A (en) Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2-aminocyclohepta(b)benzofurans
MY119342A (en) Pesticidal pyrazoles and derivatives
ZA975638B (en) New synthetic catechol derivatives, methods of producing them and their use.
GB0119121D0 (en) Improvements in and relating to computer systems
IL135516A0 (en) Process for n-desmethylating erythromycins and derivatives thereof
MXPA98008158A (es) Composicion anti-vih que contiene derivados de imidazol.
AU3068897A (en) Process of preparing 2,2'-(1-methyl-1,2-ethanediylidene)bis{hydrazine carboximidamide}
TW343412B (en) Dynamic switch method of packet forwarding mode in a network switch
PL319024A1 (en) 4-thia-1-azabicyclo(3.2.0) heptane-3-imino-2-isopropylideno-7-ketoanalgones of beta-lactames, method of obtaining them and their application
WO2001051543A3 (en) Tricarboxylate plasticizer for halogenated polymers

Legal Events

Date Code Title Description
FF Patent granted
RH1 Patent not in force